Hypnotic drug use among 0–17 year olds during 2004–2011: A nationwide prescription database study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: To (a) describe the prevalence, trend, and amount of hypnotic drug use, (b) determine the prevalence of chronic diseases among hypnotic drug users, and (c) determine levels of recurrent hypnotic drug use (2007–2011), among 0–17 year old Norwegians. Methods: Data were obtained from the nationwide Norwegian Prescription Database (NorPD) in the period 2004–2011. Results: Hypnotic drug use in 0–17 year olds increased during the period, from 8.9 to 12.3 per 1000, mainly owing to doubling of melatonin use. Hypnotic drug use peaked at 15 per 1000 among those aged 1–2 years. Melatonin use increased steadily from 6 to 12 years of age, most pronounced in males. Among females, hypnotic drug use increased threefold from 13 to17 years of age. Melatonin was dispensed in the highest annual amount of all hypnotic drugs; accounting up to a median of 360 defined daily doses in 9–13 year old boys. A total of 62% and 52% of all male and female hypnotic drug users were co-medicated with reimbursable drugs for chronic diseases. Levels of recurrent use (2007–2011) were 12% in boys and 8% in girls, of whom 76–77% were co-medicated with drugs reimbursed for chronic diseases. Conclusions: There is a trend of increasing use of hypnotic drugs among 0–17 year olds, mainly owing to increasing use of melatonin, used in high amounts. Still, melatonin is not recommended in Norway for use in this age group because of insufficient data on safety and efficacy. A threefold increase in hypnotic drugs among females from 13 to 17 years of age warrants attention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal tracking of adolescent smoking, physical activity, and food choice behaviors
Kelder, S. H., Perry, C. L., Klepp, K. I., & Lytle, L. L. (1994) · American Journal of Public Health · doi:10.2105/ajph.84.7.1121 · Cited by 1,388 · cited 1×
“given the evidence of early consolidation and tracking of health-related behaviour into adulthood [30], exploring the increasing use of hypnotic and other drugs during adolescence is an important challenge to our society.”
BackgroundAssociation between Puberty and Delayed Phase Preference
Carskadon, M. A., Vieira, C., & Acebo, C. (1993) · Sleep · doi:10.1093/sleep/16.3.258 · Cited by 1,167
Johnson, E. O., Roth, T., Schultz, L., & Breslau, N. (2006) · Pediatrics · doi:10.1542/peds.2004-2629 · Cited by 616
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Vohra, S., Klassen, T. P., & Baker, G. (2006) · BMJ · doi:10.1136/bmj.38731.532766.f6 · Cited by 454
The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T. P., & Vohra, S. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0243.x · Cited by 399
A three-country comparison of psychotropic medication prevalence in youth
Zito, J. M., Safer, D. J., Berg, L. T. D. J.-V. D., Janhsen, K., Fegert, J. M., Gardner, J. F., Glaeske, G., & Valluri, S. C. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-26 · Cited by 201
Cited by
Current role of melatonin in pediatric neurology: Clinical recommendations
Bruni, O., Alonso-Alconada, D., Besag, F., Biran, V., Braam, W., Cortese, S., Moavero, R., Parisi, P., Smits, M., Van der Heijden, K., et al. (2015) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2014.12.007 · Cited by 280
Williams Buckley, A., Hirtz, D., Oskoui, M., Armstrong, M. J., Batra, A., Bridgemohan, C., Coury, D., Dawson, G., Donley, D., Findling, R. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009033 · Cited by 228
“Melatonin is the most commonly dispensed hypnotic drug in children.(41) However, melatonin concentrations in OTC formulations differ, and some formulations are contaminated with other products (e.”
BackgroundSafety of higher doses of melatonin in adults: A systematic review and meta-analysis
Menczel Schrire, Z., Phillips, C. L., Chapman, J. L., Duffy, S. L., Wong, G., D’Rozario, A. L., Comas, M., Raisin, I., Saini, B., Gordon, C. J., et al. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12782 · Cited by 133
Masi, G., Fantozzi, P., Villafranca, A., Tacchi, A., Ricci, F., Ruglioni, L., Inguaggiato, E., Pfanner, C., & Cortese, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s193891 · Cited by 34
“Indeed, it is one of the most commonly used drugs for sleep problems in infants, children and adolescents, in particular those with neurodevelopmental disorders.(15) Proof of the efficacy of melatonin in sleep latency and sleep duration in ADHD children has been supported by observational studies.”
BackgroundFurster, C., & Hallerbäck, M. U. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1866-3 · Cited by 19
“The prevalence of hypnotic drug use in children in Norway increased during the period 2004–2011, and this was attributed to the use of melatonin [18].”
Metadata
- Authors
- Hartz, I., Furu, K., Bratlid, T., Handal, M., & Skurtveit, S.
- Venue
- Scandinavian Journal of Public Health
- Publisher
- SAGE Publications
- Published
- 2012-10-29
- Volume
- 40
- Issue
- 8
- Pages
- 704-711
- ISSN
- 1403-4948 (ISSN-L)
- 1651-1905
- OpenAlex
- W2053543232
- Cited by
- 55
- References
- 6
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.